Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Minerva Neurosciences Inc.
Headquarters: Waltham, MA, United States of America
Website: http://www.minervaneuroscie...
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Rémy Henri Luthringer, PhD
Number Of Employees: 8
Enterprise Value: $55,363,864
PE Ratio: 8.52
Exchange/Ticker 1: NASDAQ:NERV
Exchange/Ticker 2: N/A
Latest Market Cap: $11,329,300
BioCentury | Mar 12, 2024
Product Development
Clinical report: takeaways from Amylyx’s ALS journey
Plus: A comeback for Regulus? And updates from Acadia, MoonLake, Ventyx, Acelyrin, Sanofi and more
BioCentury | Feb 28, 2024
Regulation
Minerva setback doesn’t preclude big year for schizophrenia
With Karuna’s PDUFA date and several readouts on the way, 2024 is still looking like an important year for progress in treating the disease
BioCentury | Feb 8, 2024
Product Development
Bristol Myers’ growing challenge
The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff
BioCentury | Feb 1, 2024
Data Byte
World’s first TIL therapy among FDA’s five February PDUFA dates
An approval for Iovance’s lifileucel would mark the entry of immune cell therapies into solid tumors
BioCentury | Jan 30, 2024
Finance
Biotech IPOs & momentum in the IL-18 field: BioCentury’s latest podcast
Plus: the schizophrenia pipeline and what’s next for Singapore biotech
BioCentury | Jan 24, 2024
Data Byte
Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024
A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
BioCentury | May 2, 2023
Finance
May 1 Quick Takes: Acelyrin could be NASDAQ’s biggest biotech IPO in two years
Plus: Translational inhibition company Initial launches with $75M from ATP and updates from Biogen, Ascendis, Minerva, Teva-MedinCell, BMS, Avadel
BioCentury | Oct 18, 2022
Deals
Oct. 17 Quick Takes: Gilead, MacroGenics in deal for bispecific
Biogen’s ALS candidate delayed, plus updates from Oculis, Treeline, Minerva, Acrivon and more
BioCentury | Oct 1, 2021
Finance
Sept. 30 Quick Takes: Advent closes €86M second fund
Data for Sanofi’s anti-OX40 mAb, plus TrialSpark’s $156M series C, Minerva’s next step toward schizophrenia submission and more
BioCentury | Jun 14, 2021
Management Tracks
J&J’s Burton named Moderna CMO; plus Editas, Athira, Yumanity and more
Paul Burton will become CMO at Moderna Inc. (NASDAQ:MRNA) on July 6, succeeding Tal Zaks. Burton is a 16-year veteran of Johnson & Johnson (NYSE:JNJ), most recently serving as chief global medical
Items per page:
1 - 10 of 52